Analyst Mike Matson highlighted that the growth story for Boston Scientific depends heavily on its cardiac implant, Watchman. Watchman is a medical device that's effectively designed to reduce the ...

“Globally, we surpassed 500,000 patients treated with a Watchman device driven by our innovation, clinical evidence and patient-awareness efforts,” Mahoney said. Boston Scientific’s business ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...

Boston Scientific Corporation BSX is scheduled to ... Access solutions products, POLARx FIT and WATCHMAN FLX. Performance in China is expected to have been led by the company’s advanced ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...

The company is also preparing for the anticipated results of the OPTION trial, which evaluates the potential market expansion for Boston Scientific's WATCHMAN device. Analysts from Stifel have ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

Warning! GuruFocus has detected 5 Warning Sign with BSX. Analyst Mike Matson highlighted that the growth story for Boston Scientific depends heavily on its cardiac implant, Watchman. Watchman is a ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

J.P. Morgan analysts are looking for heart device Watchman to contribute this quarter and accelerate if its label is expanded next year. Boston Scientific is also set to share transcatheter aortic ...